Skip to main
  1. Stocks
  2. MetLife
  3. Forecast
MET

MetLife (MET) Stock Forecast & Price Target

MetLife (MET) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

MetLife is attractive because its diversified earnings base across Group Benefits, RIS, Asia, Latin America, EMEA, and MIM supports consistent profitability, with 3Q EPS of $2.78 modestly ahead of consensus and adjusted ROE near 20% helped by strong VII. Its U.S. franchises and international segments are all contributing, while capital-light businesses such as Group Benefits and Latin America should lift free cash flow, improve mix, and sustain earnings growth even as some mortality and disability trends normalize gradually. The firm also appears to be executing well on expenses and capital deployment, with a sub-12.1% direct expense ratio target, expected full-year 2026 VII above $1.6 billion, and management confidence that 2026 adjusted ROE will exceed the 15%–17% range.

Bears say

MetLife is viewed negatively because its earnings are highly exposed to lower interest rates, credit spread widening, and market volatility, which can pressure net investment income, reserve adequacy, and investment portfolio values. The company also faces downside from below-expected alternative asset returns, a possible slowdown in wage and employment growth, and mortality normalization, all of which could weaken profitability across its insurance and annuity businesses. Despite a diversified footprint with Group Benefits and RIS at around 52% of 2025 adjusted earnings, Asia at about 25%, and Latin America near 14% of 2024 earnings, global competition, FX risk, and regulatory uncertainty create material margin and growth pressure.

MetLife (MET) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MetLife and is not a guaranteed prediction by Public.com or investment advice.

MetLife (MET) Analyst Forecast & Price Prediction

Get the latest MetLife (MET) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MetLife (MET)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MetLife (MET) Forecast

Analysts have given MetLife (MET) a Buy based on their latest research and market trends.

According to 12 analysts, MetLife (MET) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $109.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $109.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MetLife (MET)


MetLife (MET) Analyst Forecast & Price Prediction

Get the latest MetLife (MET) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MetLife (MET)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MET stock data and trends